XML 49 R38.htm IDEA: XBRL DOCUMENT
v3.26.1

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | 1 Months Ended | 6 Months Ended
--- | --- | ---
Dec. 31, 2024 | Feb. 28, 2021 | Dec. 31, 2020 | Nov. 30, 2018 | Jun. 30, 2026
Regeneron Pharmaceuticals Inc [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Term of agreement |  | 5 years |  |  |
BeiGene Swizerland Gmb H [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Term of agreement | 7 years |  |  |  |
Ateganosine THIO Therapeutics Inc [Member] | Amended Patent and Technology License Agreement [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Term of agreement |  |  |  | 20 years |
Combined milestone payment maximum |  |  |  | $ 112,000,000 |
Ateganosine THIO Therapeutics Inc [Member] | Amended Patent and Technology License Agreement [Member] | Minimum [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Milestone payment |  |  |  | $ 1,000,000 |
Ateganosine THIO Therapeutics Inc [Member] | Amended Patent and Technology License Agreement [Member] | Minimum [Member] | Net Sales Up to $1,000,000,000 [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Rate of royalties on net sales |  |  |  | 2.00% |
Ateganosine THIO Therapeutics Inc [Member] | Amended Patent and Technology License Agreement [Member] | Minimum [Member] | Net Sales Above $1,000,000,000 [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Rate of royalties on net sales |  |  |  | 2.50% |
Ateganosine THIO Therapeutics Inc [Member] | Amended Patent and Technology License Agreement [Member] | Maximum [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Milestone payment |  |  |  | $ 50,000,000 |
Ateganosine THIO Therapeutics Inc [Member] | Amended Patent and Technology License Agreement [Member] | Maximum [Member] | Net Sales Up to $1,000,000,000 [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Rate of royalties on net sales |  |  |  | 4.00% |
Ateganosine THIO Therapeutics Inc [Member] | Amended Patent and Technology License Agreement [Member] | Maximum [Member] | Net Sales Above $1,000,000,000 [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Rate of royalties on net sales |  |  |  | 5.00% |
University of Texas Southwestern [Member] | Amended Patent and Technology License Agreement [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Payments due related to milestones |  |  |  |  | $ 0
University of Texas Southwestern [Member] | Patent and Technology License Agreement [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Term of agreement |  |  | 20 years |  |
Combined milestone payment maximum |  |  | $ 112,000,000 |  |
Percentage of royalty description |  |  |  |  | There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the UTSW2 Agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by 50%.
University of Texas Southwestern [Member] | Patent and Technology License Agreement [Member] | Minimum [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Milestone payment |  |  | $ 1,000,000 |  |
University of Texas Southwestern [Member] | Patent and Technology License Agreement [Member] | Minimum [Member] | Net Sales Up to $1,000,000,000 [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Rate of royalties on net sales |  |  | 2.00% |  |
University of Texas Southwestern [Member] | Patent and Technology License Agreement [Member] | Minimum [Member] | Net Sales Above $1,000,000,000 [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Rate of royalties on net sales |  |  | 2.50% |  |
University of Texas Southwestern [Member] | Patent and Technology License Agreement [Member] | Maximum [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Milestone payment |  |  | $ 50,000,000 |  |
University of Texas Southwestern [Member] | Patent and Technology License Agreement [Member] | Maximum [Member] | Net Sales Up to $1,000,000,000 [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Rate of royalties on net sales |  |  | 4.00% |  |
University of Texas Southwestern [Member] | Patent and Technology License Agreement [Member] | Maximum [Member] | Net Sales Above $1,000,000,000 [Member] |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |
Rate of royalties on net sales |  |  | 5.00% |  |

X
- Definition Combined milestone payments maximum. + References No definition available. + Details
Name: | MAIA_CombinedMilestonePaymentsMaximum
Namespace Prefix: | MAIA_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | MAIA_MilestonePayment
Namespace Prefix: | MAIA_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments due related to milestones. + References No definition available. + Details
Name: | MAIA_PaymentsDueRelatedToMilestones
Namespace Prefix: | MAIA_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of royalty payments on net sales. + References No definition available. + Details
Name: | MAIA_PercentageOfRoyaltyPaymentsOnNetSales
Namespace Prefix: | MAIA_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty payments on net sales description. + References No definition available. + Details
Name: | MAIA_PercentageOfRoyaltyPaymentsOnNetSalesDescription
Namespace Prefix: | MAIA_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of agreement. + References No definition available. + Details
Name: | MAIA_TermOfAgreement
Namespace Prefix: | MAIA_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482645/405-30-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.W.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 275 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=MAIA_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=MAIA_BeiGeneSwizerlandGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MAIA_AteganosineTHIOTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=MAIA_AmendedPatentAndTechnologyLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=MAIA_NetSalesUptoOneBillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=MAIA_NetSalesAboveOneBillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MAIA_UniversityOfTexasSouthwesternMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=MAIA_PatentAndTechnologyLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |